demonstrated that impairing STAT3 signaling cascade with small-molecule STAT3 inhibitor, C188-9, which binds to the phosphotyrosyl peptide binding site within STAT3, has significantly reduced the tyrosine phosphorylation status of STAT3 in prostate cancer cells (63). This evidence concerns the gene STAT3 and prostate carcinoma.